Jeffrey M. Bockman PhD

Expert Advisor, Executive Vice President, Oncology

Jeff leads the Oncology and Virology Practices at Lumanity. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Cello Health BioConsulting, now Lumanity. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.

Before joining Cello Health BioConsulting, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients – Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions – and holds four patents in the use of ribozymes.

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.

Jeff is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).

Jeff is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, an advisor to the JPM Biotech Showcase, a member of the Advisory "Group" to Skipper Bio Med (a preclinical research consultancy that provides pro bono services to academic and industry groups, developing promising lung and/or pancreatic cancer therapeutics/device. Skipper is fully supported by a private US family that has been personally impacted by these cancers and is committed to bridging the research “valley of death”).

Jeff is also part of the Clinical Advisory Board of ImmunOS (an immunotherapy company based in Zurich) and the Scientific Advisory Board of hC Bioscience (a novel RNA-based platform company in Cambridge, MA).